Dostinex 0,5 mg Pfizer Labs

Features and description of Dostinex 0,5 mg Pfizer Labs

Dostinex is a known prolactin inhibitor. It reduces the secretion of this hormone to protect athletes taking certain types of anabolic steroids from side effects. The active ingredient in Dostinex 0,5 mg Pfizer Labs is cabergoline. It is of plant origin and is widely used in medicine.

How Dostinex 0,5 mg Pfizer Labs affects the body

The drug only works if the athlete is taking steroids that increase prolactin. For example, Deca-Durabolin or trenbolone. Dostinex has the following effects:

• eliminates the side effects of the steroid;
• increases libido;
• improves erection;
• promotes rapid recovery and preparation for the next sexual intercourse;
• lowers blood pressure.

Since prolactin can cause gynecomastia and bloating, this drug helps to avoid them. It removes excess water, so muscle mass becomes drier and more prominent.

Negative consequences

They appear in rare cases if a person has an individual intolerance or uses too high a dose. The most common problems are:

• nausea
• constipation
• dry mouth;
• depression
• insomnia;
• dyspnoea.

The unpleasant symptoms pass on their own and quickly. But if you do not feel well, consult a doctor, you may need to choose another medicine.

Features of use

To achieve the effect of the drug, you do not need to take large doses. For prevention, you can take half a tablet (0.25 mg) with an interval of 7-21 days, depending on the course of steroids taken. It is necessary to monitor the prolactin level to find the right amount and appropriate intervals.

If the hormone level is already high, take half a tablet every 4 days and monitor blood tests for prolactin.

Dostinex 0,5 mg Pfizer Labs is taken with a sharp increase in prolactin and the side effects caused by this hormone. Daily intake of the drug is not necessary, but such a diet is sometimes used if the prolactin level is very high.

List of references

1. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994 May 5;330(18):1369-76. doi: 10.1056/NEJM199405053301801. PMID: 7908411.
2. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997 Mar;82(3):876-83. doi: 10.1210/jcem.82.3.3800. PMID: 9062505.
3. Lamberts SW, van Koetsveld PM, van der Lely AJ. The role of dopamine agonists in the medical therapy of prolactinomas. Pituitary. 1996 Apr; 9(2): 163–178. doi: 10.1007/BF01758580. PMID: 8842553; PMCID: PMC3457130.
4. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997 Sep;82(9):2102-7. doi: 10.1210/jcem.82.7.4095. PMID: 9253356.
5. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994 May 5;330(18):1369-76. doi: 10.1056/NEJM199405053301801. PMID: 7908411.